These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 16773200)

  • 21. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone and biological characteristics of breast cancers in postmenopausal women.
    Secreto G; Venturelli E; Meneghini E; Greco M; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.
    Rinaldi S; Kaaks R; Zeleniuch-Jacquotte A; Arslan AA; Shore RE; Koenig KL; Dossus L; Riboli E; Stattin P; Lukanova A; Toniolo P
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):48-52. PubMed ID: 15668475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
    Johansson H; Gandini S; Bonanni B; Mariette F; Guerrieri-Gonzaga A; Serrano D; Cassano E; Ramazzotto F; Baglietto L; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2008 Mar; 108(1):57-67. PubMed ID: 17468953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fasting glucose is a risk factor for breast cancer: a prospective study.
    Muti P; Quattrin T; Grant BJ; Krogh V; Micheli A; Schünemann HJ; Ram M; Freudenheim JL; Sieri S; Trevisan M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1361-8. PubMed ID: 12433712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status.
    Barnes BB; Chang-Claude J; Flesch-Janys D; Kinscherf R; Schmidt M; Slanger T; Bonaterra G; Steindorf K
    Cancer Causes Control; 2009 Dec; 20(10):1985-96. PubMed ID: 19597750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
    Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer.
    Serrano ML; Romero A; Cendales R; Sánchez-Gómez M; Bravo MM
    Biomedica; 2006 Jun; 26(2):258-68. PubMed ID: 16925098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women.
    Zeleniuch-Jacquotte A; Toniolo P; Levitz M; Shore RE; Koenig KL; Banerjee S; Strax P; Pasternack BS
    Cancer Epidemiol Biomarkers Prev; 1995 Dec; 4(8):857-60. PubMed ID: 8634657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
    Tworoger SS; Mantzoros C; Hankinson SE
    Obesity (Silver Spring); 2007 Sep; 15(9):2217-24. PubMed ID: 17890489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study.
    Cummings SR; Lee JS; Lui LY; Stone K; Ljung BM; Cauleys JA
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1047-51. PubMed ID: 15894651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
    Oh JC; Wu W; Tortolero-Luna G; Broaddus R; Gershenson DM; Burke TW; Schmandt R; Lu KH
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):748-52. PubMed ID: 15159305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk.
    Zhao H; Grossman HB; Spitz MR; Lerner SP; Zhang K; Wu X
    J Urol; 2003 Feb; 169(2):714-7. PubMed ID: 12544349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.